Pacira Biosciences, Inc. (PCRX)
| Market Cap | 2.60B |
| Revenue (ttm) | 442.99M |
| Net Income (ttm) | 147.73M |
| Shares Out | 43.83M |
| EPS (ttm) | 3.33 |
| PE Ratio | 17.73 |
| Forward PE | 20.75 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $58.95 |
| Previous Close | $60.08 |
| Change ($) | -1.13 |
| Change (%) | -1.88% |
| Day's Open | 59.61 |
| Day's Range | 58.65 - 60.45 |
| Day's Volume | 384,296 |
| 52-Week Range | 48.23 - 80.00 |
Results demonstrate the addition of preoperative iovera° treatment to a multimodal pain management protocol leads to improved outcomes during 6-week recovery period Results demonstrate the addition of p...
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PARSIPPANY, N.J., July 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on...
Pacira BioSciences (PCRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
-- EXPAREL average daily sales for May 2021 were 162% of May 2020 -- -- EXPAREL momentum continues with average daily sales for May 2021 at 105% of April 2021 --
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal fossa) and saphenous (in adductor cana...
-- Study did not demonstrate statistical significance for primary endpoint of pain reduction from 0 to 96 hours for EXPAREL versus bupivacaine HCl -- -- EXPAREL achieves highly statistically significant...
Composition claims for EXPAREL 200-liter process extend patent protection into 2041 Composition claims for EXPAREL 200-liter process extend patent protection into 2041
PARSIPPANY, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 RBC Capital Markets Global Healthcare Conference at 10:20 AM E...
Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.
Pacira (PCRX) delivered earnings and revenue surprises of -10.17% and 1.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
-- EXPAREL average daily sales at 115% of the prior year first quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: ...
PARSIPPANY, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on...
NEW YORK, April 20, 2021 /PRNewswire/ -- Spine BioPharma, LLC, a company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain ca...
Complaint challenges the American Society of Anesthesiologists for promoting biased, analytically misguided studies in its journal, on its website, and through CME activity Complaint challenges the Amer...
EXPAREL average daily sales at 115% of the prior year for the first quarter and 137% of the prior year for the month of March EXPAREL average daily sales at 115% of the prior year for the first quarter ...
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
This healthcare stock just got great news from the Food and Drug Administration.
The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.
-- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over –-- Conference call tomorrow at 8:30 a.m. ET -- PARSIPPANY, N.J., March 22, 2021 (GLOBE NEWSWIRE)...
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...
-- EXPAREL average daily sales at 103% of the prior year for the month of February 2021 -- PARSIPPANY, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry lead...
PARSIPPANY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Barclays Global Healthcare Conference at 10:55 AM ET on Tues...
Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.
Pacira (PCRX) delivered earnings and revenue surprises of 6.10% and -0.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
— Reports record full-year 2020 revenue of $429.6 million —
PARSIPPANY, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results befor...
EXPAREL average daily sales at 108% of the prior year for the month of January 2021 EXPAREL average daily sales at 108% of the prior year for the month of January 2021
Supports Development of Promising Gene Therapy Platform for Osteoarthritis Supports Development of Promising Gene Therapy Platform for Osteoarthritis
AMRX vs. PCRX: Which Stock Is the Better Value Option?
-- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December -- PARSIPPANY, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioScie...
PARSIPPANY, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 7:30 AM ET on We...
-- EXPAREL average daily sales at 103% of the prior year for the month of November 2020 -- PARSIPPANY, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provid...
PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference at 1...
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.
--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachial plexus o...
-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- -- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 --
PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at 2:05 PM GM...
Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript
Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET --
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
--The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- PARSIPPANY, N.J., and TAMPA, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Paci...
Pacira BioSciences (PCRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
PARSIPPANY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on ...
Is (PCRX) Outperforming Other Medical Stocks This Year?
About PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid han... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 3, 2011 |
| Stock Exchange NASDAQ | Ticker Symbol PCRX |
Analyst Forecasts
According to 14 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is 80.08, which is an increase of 35.84% from the latest price.